GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Return-on-Tangible-Asset

InflaRx NV (InflaRx NV) Return-on-Tangible-Asset

: -51.64% (As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. InflaRx NV's annualized Net Income for the quarter that ended in Dec. 2023 was $-69.49 Mil. InflaRx NV's average total tangible assets for the quarter that ended in Dec. 2023 was $134.57 Mil. Therefore, InflaRx NV's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -51.64%.

The historical rank and industry rank for InflaRx NV's Return-on-Tangible-Asset or its related term are showing as below:

IFRX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -137.4   Med: -37.51   Max: -20.69
Current: -37.54

During the past 9 years, InflaRx NV's highest Return-on-Tangible-Asset was -20.69%. The lowest was -137.40%. And the median was -37.51%.

IFRX's Return-on-Tangible-Asset is ranked better than
51.83% of 1555 companies
in the Biotechnology industry
Industry Median: -40.28 vs IFRX: -37.54

InflaRx NV Return-on-Tangible-Asset Historical Data

The historical data trend for InflaRx NV's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.51 -34.24 -41.58 -25.04 -38.88

InflaRx NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.17 -47.32 -30.09 -22.55 -51.64

Competitive Comparison

For the Biotechnology subindustry, InflaRx NV's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV Return-on-Tangible-Asset Distribution

For the Biotechnology industry and Healthcare sector, InflaRx NV's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Return-on-Tangible-Asset falls into.



InflaRx NV Return-on-Tangible-Asset Calculation

InflaRx NV's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-46.53/( (108.328+131.014)/ 2 )
=-46.53/119.671
=-38.88 %

InflaRx NV's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-69.488/( (138.119+131.014)/ 2 )
=-69.488/134.5665
=-51.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


InflaRx NV  (NAS:IFRX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


InflaRx NV Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Industry
Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.